+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Growth Opportunities in Stem Cell Therapy, Nucleotide Drugs, and Therapeutics for Cancer and Infectious Diseases

  • PDF Icon


  • 48 Pages
  • June 2021
  • Region: Global
  • Frost & Sullivan
  • ID: 5406909

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations focused on stem cell therapy - both allogeneic and autologous. A number of emerging technologies have been discussed for a variety of therapeutic indications including cancer, autoimmune diseases, and neurological disorders. Further, innovations on nucleic acid drugs and novel drug delivery systems have also been covered. Few innovations highlight developments in oral pox drugs, chemotherapeutics, and artificial lactoferrin

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Table of Contents

1. Innovations in Life Sciences, Health & Wellness

  • Photodynamic Therapy for Cutaneous Metastatic Breast Cancer
  • Rem-001 Therapy for CMBC
  • Kintara Therapeutics - Investor Dashboard
  • Next Generation Therapy for Stem Cell Mobilization
  • Therapy for Solid Organ Transplants
  • Talaris Therapeutics - Investor Dashboard
  • Stem Cell Mobilization and Collection
  • Mgta-145 for Stem Cell Transplants
  • Magenta Therapeutics - Investor Dashboard
  • Genetically Engineered Red Blood Cell Therapeutic Platform
  • Rtx-240 Therapy for Cancer Treatment
  • Rubius Therapeutics - Investor Dashboard
  • Nk-Cell Therapy for Cancer Treatment
  • Potent Immunotherapy for Cancer Treatment
  • Kiadis Pharma N.V. - Investor Dashboard
  • Therapeutic Stem Cell Technology
  • Treatment for Rare Diseases
  • Kangstem Biotech - Investor Dashboard
  • Autologous Cellular Therapy for Neurodegenerative Diseases
  • Nurown Msc-Ntf Technology
  • Brainstorm Cell Therapeutics - Investor Dashboard
  • Cell Engineering Platform for Unmet Medical Needs
  • Transformative Cell Therapy for Multiple Disease Areas
  • Sana Biotechnology - Investor Dashboard
  • Allogeneic Cellular Therapy for Bone Disorders
  • Bone Therapeutics is Offering an Off-The-Shelf Product for Bone Disorders
  • Bone Therapeutics - Investor Dashboard
  • Developing Spatial Omics
  • Developing Cell-Based Lactoferrin
  • Calcium-Based Bone Void Fillers
  • Intravenous Therapy for Treating Pulmonary Hypertension Associated with Heart Failure and Preserved Ejection Fraction
  • Oral Red Blood Cell Pyruvate Kinase-R Therapy for Treating Sickle Cell Disease
  • Senotherapeutics to Reverse Ageing
  • Next-Generation Nucleic Acid-Based Cancer Therapy Using Novel Delivery System
  • Centronuclear Myopathies Therapy Using Antisense Oligonucleotide
  • Oral Smallpox Medication for Adult and Pediatric Patients
  • Synthetic Hormone Mimetic for the Treatment of Polycythemia Vera

2. Key Contacts

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bone Therapeutics
  • Brainstorm Cell Therapeutics
  • Kangstem Biotech
  • Kiadis Pharma N.V.
  • Kintara Therapeutics
  • Magenta Therapeutics
  • Rubius Therapeutics
  • Sana Biotechnology
  • Talaris Therapeutics